Questions about Atrial Fibrillation? Get answers from our expert.

Generic Name: Indomethacin
Class: Other Nonsteroidal Anti-inflammatory Agents
CAS Number: 53-86-1

Warning(s)

  • Cardiovascular Risk
  • Possible increased risk of serious (sometimes fatal) cardiovascular thrombotic events (e.g., MI, stroke).420 Risk may increase with duration of use.420 Individuals with cardiovascular disease or risk factors for cardiovascular disease may be at increased risk.420 (See Cardiovascular Effects under Cautions.)

  • Contraindicated for the treatment of pain in the setting of CABG surgery.420

  • GI Risk
  • Increased risk of serious (sometimes fatal) GI events (e.g., bleeding, ulceration, perforation of the stomach or intestine).420 Serious GI events can occur at any time and may not be preceded by warning signs and symptoms.420 Geriatric individuals are at greater risk for serious GI events.420 (See GI Effects under Cautions.)

Introduction

Prototypical NSAIA; indoleacetic acetic acid derivative.301 341 420

Uses for Indocin

When used for inflammatory diseases, consider potential benefits and risks of indomethacin therapy as well as alternative therapies before initiating therapy with the drug.420 Use lowest effective dosage and shortest duration of therapy consistent with the patient’s treatment goals.420

Inflammatory Diseases

Symptomatic treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.341 420

Symptomatic relief of acute gout and acute painful shoulder (i.e., bursitis and/or tendinitis).341 420

Slideshow: Living with Your Migraines: Tips for Treatment and Prevention

Management of juvenile rheumatoid arthritis in children ≥2 years of age.420

Patent Ductus Arteriosus (PDA)

Treatment of PDA in premature neonates.301 302 303 304 305 306 308 309 310 311 312 313 314 316 318 319 320 322 323 324 325 326 Used to promote closure of a hemodynamically significant PDA (i.e., left-to-right shunt large enough to compromise cardiorespiratory status) in premature neonates weighing 500–1750 g when 36–48 hours of usual medical management (e.g., fluid restriction, diuretics, cardiac glycosides, respiratory support) is ineffective.301 306 307 313

Pericarditis

Reduction of pain, fever, and inflammation of pericarditis;a however, other drugs (i.e., aspirin) generally are preferred.452

Indocin Dosage and Administration

General

  • For inflammatory diseases, consider potential benefits and risks of indomethacin therapy as well as alternative therapies before initiating therapy with the drug.420

Administration

Administer orally or rectally (for inflammatory diseases or pericarditis)341 420 or by IV infusion (for PDA).301

Oral Administration

In patients who have persistent night pain and/or morning stiffness, a large portion (maximum 100 mg) of the total daily dose may be given at bedtime.341 420

Conventional Capsules and Oral Suspension

Administer conventional capsules and oral suspension in 2–4 divided doses daily.420

Extended-release Capsules

Administer extended-release capsules once or twice daily.341

Extended-release capsules can be used as an alternative to conventional capsules: 75 mg once daily (extended-release) as an alternative to 25 mg 3 times daily (conventional); 75 mg twice daily (extended-release) as an alternative to 50 mg 3 times daily (conventional).341

Swallow extended-release capsules intact.341

Extended-release capsules are not recommended for treatment of acute gouty arthritis.341

Rectal Administration

Administer in 2–4 divided doses daily.420

Retain suppositories in rectum for ≥1 hour to ensure complete absorption.420

IV Administration

For solution and drug compatibility information, see Compatibility under Stability.

Administer by IV infusion.301

Avoid extravasation (irritating to extravascular tissues).301

Reconstitution

Reconstitute vial containing 1 mg of indomethacin with 1 or 2 mL of preservative-free 0.9% sodium chloride injection or sterile water for injection to provide a solution containing 1 mg/mL or 0.5 mg/mL, respectively.301 Further dilution is not recommended.301

Use of bacteriostatic water for injection containing benzyl alcohol is not recommended because of potential risk of benzyl alcohol exposure if administered to a neonate.301

Prepare solutions immediately before use; discard any unused solution.301

Rate of Administration

Optimum rate not established; may administer dose over 20–30 minutes.301

Dosage

Available as indomethacin and indomethacin sodium; dosage expressed in terms of indomethacin.301 341 420

To minimize the potential risk of adverse cardiovascular and/or GI events, use lowest effective dosage and shortest duration of therapy consistent with the patient’s treatment goals.420 Adjust dosage based on individual requirements and response; attempt to titrate to the lowest effective dosage.420

Pediatric Patients

Inflammatory Diseases
Juvenile Rheumatoid Arthritis
Oral

Children ≥2 years of age: Initially, 1–2 mg/kg daily in divided doses.341 420 Increase dosage until a satisfactory response is achieved, up to maximum dosage of 3 mg/kg daily or 150–200 mg daily (whichever is less) in divided doses; limited data support the use of a maximum dosage of 4 mg/kg daily or 150–200 mg daily (whichever is less) in divided doses.341 420 As symptoms subside, reduce dosage to the lowest effective level or discontinue the drug.341 420

PDA
IV

Each course of therapy consists of up to 3 doses administered at 12- to 24-hour intervals.301

Base dosage on neonate’s age at the time therapy is initiated.301

Dosage for the Management of PDA in Neonates

Age at First Dose

First Dose

Second Dose

Third Dose

<48 hours

0.2 mg/kg

0.1 mg/kg

0.1 mg/kg

2–7 days

0.2 mg/kg

0.2 mg/kg

0.2 mg/kg

>7 days

0.2 mg/kg

0.25 mg/kg

0.25 mg/kg

If anuria or oliguria (urine output <0.6 mL/kg per hour) is present at the time of a second or third dose, withhold the dose until laboratory determinations indicate that renal function has returned to normal.301

If ductus arteriosus closes or is substantially constricted 48 hours or longer after completion of the first course, no further doses are necessary.301

If ductus reopens, a second course of 1–3 doses may be administered.301 Surgical ligation may be necessary if ductus is unresponsive to 2 courses of therapy.301

Pericarditis
Oral

50–100 mg daily in 2–4 divided doses.a

Adults

Inflammatory Diseases
Osteoarthritis, Rheumatoid Arthritis, or Ankylosing Spondylitis
Oral

Conventional capsules or oral suspension: Initially, 25 mg 2 or 3 times daily.420 If needed, increase dosage by 25 or 50 mg daily at weekly intervals until a satisfactory response is obtained up to a maximum dosage of 150–200 mg daily.420

Extended-release capsules: Initially, 75 mg once daily.341 May increase dosage to 75 mg twice daily.341

Rectal

25 mg 2 or 3 times daily. If needed, increase dosage by 25 or 50 mg daily at weekly intervals until a satisfactory response is obtained up to a maximum dosage of 150–200 mg daily.420

Gout
Oral

Conventional capsules: 50 mg 3 times daily until pain is tolerable; then reduce dosage rapidly and discontinue.420

Painful Shoulder
Oral

Conventional capsules or oral suspension: 75–150 mg daily in 3 or 4 divided doses.420 Discontinue once symptoms have been controlled for several days; usual course of therapy is 7–14 days.420

Extended-release capsules: 75 mg once or twice daily.341 Discontinue once symptoms have been controlled for several days; usual course of therapy is 7–14 days.341

Rectal

75–150 mg daily in 3 or 4 divided doses.420 Discontinue once symptoms have been controlled for several days; usual course of therapy is 7–14 days.420

Pericarditis
Oral

75–200 mg daily in 3 or 4 divided doses.a

Prescribing Limits

Pediatric Patients

Juvenile Rheumatoid Arthritis
Oral

Maximum 4 mg/kg or 150–200 mg daily, whichever is less.420

Adults

Inflammatory Diseases
Rheumatoid Arthritis, Osteoarthritis, or Ankylosing Spondylitis
Oral

Maximum 200 mg daily.420

Rectal

Maximum 200 mg daily.420

Special Populations

Geriatric Patients

Careful dosage selection recommended due to possible age-related decreases in renal function.341 420

Cautions for Indocin

Contraindications

  • Known hypersensitivity to indomethacin or any ingredient in the formulation.341 420

  • History of asthma, urticaria, or other sensitivity reaction precipitated by aspirin or other NSAIAs.341 420

  • Treatment of perioperative pain in the setting of CABG surgery.420

  • When administered rectally, history of proctitis or recent rectal bleeding.420

  • When used for PDA, known or suspected untreated infection; bleeding, especially active intracranial hemorrhage or GI bleeding; thrombocytopenia; coagulation defects; known or suspected necrotizing enterocolitis; substantial renal impairment; congenital heart disease if patency of the ductus arteriosus is necessary for pulmonary or systemic blood flow (e.g., pulmonary atresia, severe tetralogy of Fallot, severe coarctation of the aorta).301

Warnings/Precautions

Warnings

Cardiovascular Effects

Selective COX-2 inhibitors have been associated with an increased risk of cardiovascular events in certain situations.484 Several prototypical NSAIAs also have been associated with an increased risk of cardiovascular events.487 488 489 Current evidence suggests that use of indomethacin is associated with increased cardiovascular risk.487 488 489 490

Use NSAIAs with caution and careful monitoring (e.g., monitor for development of cardiovascular events), and at the lowest effective dosage for the shortest duration necessary.420

Short-term use to relieve acute pain, especially at low dosages, does not appear to be associated with increased risk of serious cardiovascular events (except immediately following CABG surgery).484

No consistent evidence that concomitant use of low-dose aspirin mitigates the increased risk of serious adverse cardiovascular events associated with NSAIAs.420 (See Specific Drugs under Interactions.)

Hypertension and worsening of preexisting hypertension reported; either event may contribute to the increased incidence of cardiovascular events.420 Use with caution in patients with hypertension; monitor BP.420 Impaired response to certain diuretics may occur.420 (See Specific Drugs under Interactions.)

Fluid retention and edema reported.341 420 Caution in patients with fluid retention or heart failure.341 420

Deterioration of circulatory hemodynamics reported in patients with severe heart failure and hyponatremia.341 420

GI Effects

Serious GI toxicity (e.g., bleeding, ulceration, perforation) can occur with or without warning symptoms; increased risk in those with a history of GI bleeding or ulceration, geriatric patients, smokers, those with alcohol dependence, and those in poor general health.420

Incidence of major GI bleeding reported in neonates receiving IV indomethacin in clinical studies similar to that in neonates receiving placebo; minor GI bleeding occurred more frequently in indomethacin-treated neonates.301

When used for inflammatory diseases in patients at high risk for complications from NSAIA-induced GI ulceration (e.g., bleeding, perforation), consider concomitant use of misoprostol;457 464 alternatively, consider concomitant use of a proton-pump inhibitor (e.g., omeprazole)457 464 or use of an NSAIA that is a selective inhibitor of COX-2 (e.g., celecoxib).464

Renal Effects

Direct renal injury, including renal papillary necrosis, reported in patients receiving long-term NSAIA therapy.341 420

Potential for overt renal decompensation.341 420 Increased risk of renal toxicity in adults with renal or hepatic impairment or heart failure, in patients with volume depletion, in geriatric patients, and in those receiving a diuretic, ACE inhibitor, or angiotension II receptor antagonist.420 486 (See Renal Impairment under Cautions.)

May precipitate renal insufficiency in neonates; increased risk in those with extracellular volume depletion, CHF, sepsis, or hepatic dysfunction or those receiving concomitant therapy with a nephrotoxic drug.301 If a substantial reduction in urine output occurs, withhold additional doses until output returns to normal.301 (See PDA under Dosage and Administration.)

Hyponatremia reported in neonates.301 302 303 306 314 324 325 326 329 348 371 Monitor renal function and serum electrolytes.301

Hyperkalemia reported in adults.341 420

Hematologic Effects

Potential for spontaneous intraventricular hemorrhage in neonates.301 Observe premature infants for signs of bleeding.301

Contraindicated in neonates who are bleeding and in those with thrombocytopenia or coagulation defects.301

Ocular Effects

Corneal deposits and retinal disturbances reported in patients receiving long-term therapy.341 420 Ophthalmic examination recommended in patients with blurred vision; periodic ophthalmic examinations recommended in patients receiving long-term therapy.341 420

CNS Effects

May aggravate depression or other psychiatric disturbances, epilepsy, or parkinsonism; use with caution in patients with these conditions.341 420

May cause drowsiness; may impair ability to perform activities requiring mental alertness.341 420

May cause headache.341 420 Discontinue the drug in patients in whom indomethacin-induced headache persists despite a reduction in dosage.341 420

Sensitivity Reactions

Hypersensitivity Reactions

Anaphylactoid reactions (e.g., anaphylaxis, angioedema) reported.341 420

Immediate medical intervention and discontinuance for anaphylaxis.341 420

Avoid in patients with aspirin triad (aspirin sensitivity, asthma, nasal polyps); caution in patients with asthma.341 420

Dermatologic Reactions

Serious skin reactions (e.g., exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis) reported; can occur without warning.420 Discontinue at first appearance of rash or any other sign of hypersensitivity (e.g., blisters, fever, pruritus).420

General Precautions

Hepatic Effects

Severe reactions including jaundice, fatal fulminant hepatitis, liver necrosis, and hepatic failure (sometimes fatal) reported rarely with NSAIAs.341 420

Elevations of serum ALT or AST reported.341 420

Monitor for symptoms and/or signs suggesting liver dysfunction; monitor abnormal liver function test results.341 420 Discontinue if signs or symptoms of liver disease or systemic manifestations (e.g., eosinophilia, rash) occur or if liver function test abnormalities persist or worsen.301 341 420

Hematologic Precautions

Anemia reported rarely.420 Determine hemoglobin concentration or hematocrit in patients receiving long-term therapy if signs or symptoms of anemia occur.420

May inhibit platelet aggregation and prolong bleeding time.341 420 When used for inflammatory diseases, use with caution in patients with coagulation defects.341 420

Other Precautions

Not a substitute for corticosteroid therapy; not effective in the management of adrenal insufficiency.420

May mask certain signs of infection.340 341 420

Obtain CBC and chemistry profile periodically during long-term use.420

Specific Populations

Pregnancy

Category C.420 Avoid use in third trimester because of possible premature closure of the ductus arteriosus.341 420

Lactation

Distributed into milk; use not recommended.341 420

Pediatric Use

Safety and efficacy established in neonates receiving the drug for PDA.301

Safety and efficacy of oral or rectal indomethacin not established in children ≤14 years of age.341 420

Indomethacin should not be used in children 2–14 years of age unless toxicity or lack of efficacy with other drugs justifies the risk.420

Adverse effects reported in children receiving indomethacin capsules generally comparable to those reported in adults.420 Hepatotoxicity, sometimes fatal, has been reported in pediatric patients with juvenile rheumatoid arthritis.420 Periodic assessment of liver function recommended.420

Geriatric Use

Caution advised.420 Geriatric patients appear to tolerate NSAIA-induced adverse effects less well than younger individuals.341 420 Fatal adverse GI effects reported more frequently in geriatric patients than younger adults.341 420

Possible confusion or, rarely, psychosis in geriatric patients.420

Substantially eliminated by the kidney; select dosage carefully and assess renal function periodically since geriatric patients more likely to have decreased renal function.341 420

Renal Impairment

Use not recommended in patients with advanced renal disease; close monitoring of renal function advised if used.420

Common Adverse Effects

With oral therapy, nausea, dyspepsia, headache, dizziness.341 420

With rectal administration, rectal irritation, tenesmus; adverse effects associated with oral administration possible.420

With IV therapy, bleeding,301 302 303 305 306 310 315 316 322 323 346 347 348 349 350 351 352 353 354 transient oliguria,301 302 303 306 309 314 315 324 325 326 329 346 347 348 350 353 354 355 357 358 359 371 increases in serum creatinine concentrations,301 302 303 306 314 324 325 326 329 348 371 hyponatremia,301 elevated serum potassium concentrations.301

Interactions for Indocin

Protein-bound Drugs

Possible pharmacokinetic interaction; observe for adverse effects if used with other protein-bound drugs.a

Drugs Excreted by the Kidney

Possible pharmacokinetic interaction with drugs that rely on adequate renal function for excretion.301 In neonates receiving IV indomethacin, consider dosage adjustment for drugs that rely on adequate renal function for excretion.301

Specific Drugs

Drug

Interaction

Comments

ACE inhibitors

Reduced BP response to ACE inhibitor341 420 440 441 442 443 444 445 446 447

Possible deterioration of renal function in individuals with renal impairment420

Monitor BP341 420

Aminoglycosides (amikacin, gentamicin)

Increased plasma aminoglycoside concentrations reported in neonates receiving IV indomethacin301 372

Monitor serum aminoglycoside concentrations and renal function372

Angiotensin II receptor antagonists

Reduced BP response to angiotensin II receptor antagonist420

Possible deterioration of renal function in individuals with renal impairment420

Monitor BP420

Antacids (aluminum- or magnesium-containing)

Slight reduction or delay in peak plasma indomethacin concentrationa

Clinical importance not establisheda

Anticoagulants

Possible bleeding complications; pharmacodynamic interaction not observed in clinical studies 420

Monitor anticoagulant activity;341 420 caution advised420

Alcohol

Bleeding time prolongeda

β-adrenergic blocking agents

Reduced BP response to β-adrenergic blocking agent341 420

Monitor BP 420

Cyclosporine

Possible increase in cyclosporine toxicity341 420

Use with caution; monitor renal function341 420

Digoxin

Increased serum concentration and half-life of digoxin301 341 369 370 420

Monitor serum digoxin concentrations301 341 420

Consider digoxin dosage reduction in neonates; 369 370 monitor ECG301 369 370

Diuretics (furosemide, thiazides)

Reduced natriuretic effects301 341 420

Pharmacokinetic interaction with hydrochlorothiazide unlikely367 368

Monitor for diuretic efficacy and renal failure420

Concomitant administration of furosemide used to therapeutic advantage in neonates301 324

Diuretics (potassium-sparing)

Increased serum potassium concentrations341 420

Acute renal failure reported in adults receiving triamterene341 366 420

Should not be administered concomitantly with triamterene341 420

Hydantoins

Potential pharmacokinetic (protein binding) interactiona

Monitor for toxicitya

Hydralazine

Reduced BP response to hydralazine393

Monitor BP393

Lithium

Increased plasma lithium concentrations341 420

Monitor for lithium toxicity341 420

Methotrexate

Possible increased plasma methotrexate concentrations420

Caution advised341 420

NSAIAs

NSAIAs including aspirin: Potential for increased risk of GI toxicity with little or no increase in efficacy341 420

Aspirin: No consistent evidence that low-dose aspirin mitigates the increased risk of serious cardiovascular events associated with NSAIAs420

Aspirin: Decreased plasma indomethacin concentrations reported with concomitant aspirin (3.6 g daily) therapy341 420

Diflunisal: Increased plasma indomethacin concentrations and serious GI adverse effects reported341 420

Concomitant use not recommended341 420

Potassium supplements

Increased serum potassium concentrations362

Caution advised362

Prednisolone

Increased plasma concentrations of free prednisolone; total plasma prednisolone concentrations unchangeda

Probenecid

Increased plasma concentrations of indomethacin341 420

Select and adjust indomethacin dosage with care; lower dosage may be adequate341 420

Sulfonamides

Potential pharmacokinetic (protein binding) interactiona

Monitor for toxicitya

Sulfonylureas

Potential pharmacokinetic (protein binding) interactiona

Monitor for toxicitya

Thrombolytic agents

Possible bleeding complicationsa

Caution adviseda

Indocin Pharmacokinetics

Absorption

Bioavailability

Well absorbed from the GI tract.341 420 Almost completely absorbed following oral administration as conventional or extended-release capsules;341 420 bioavailability following rectal administration is 80–90% of that of the conventional capsule.420

Indomethacin extended-release capsules release 25 mg of drug initially and the remaining 50 mg over 12 hours.341

When administered with food, the commercially available conventional capsules and oral suspension are bioequivalent.420

Distribution

Extent

Crosses the placenta and blood-brain barrier.301

Concentrations in synovial fluid 20% of those in serum.a

Distributed into milk.341 420

Plasma Protein Binding

99% (in adults).341 420

Elimination

Metabolism

Metabolized in the liver.341 420

Elimination Route

Undergoes appreciable enterohepatic circulation.301 341 420 Following oral administration, excreted in the urine (60%) and feces (33%) as unchanged drug and metabolites.341 420

Half-life

Adults: 4.5 hours.341 420

Neonates <7 days of age: 20 hours.301

Neonates >7 days of age: 12 hours.301

Neonates weighing <1 kg: 21 hours.301

Neonates weighing >1 kg: 15 hours.301

Stability

Storage

Oral

Conventional or Extended-release Capsules

15–30°C.a 341

Suspension

<30°C; avoid temperatures >50°C.420 Protect from freezing.420

Rectal

Suppositories

<30°C; avoid temperatures >40°C (even transiently).420

Parenteral

Powder for Injection

<30°C; protect from light.301

Compatibility

For information on systemic interactions resulting from concomitant use, see Interactions.

Parenteral

Solution Compatibility

Reconstitute with preservative-free sterile water for injection or preservative-free 0.9% sodium chloride injection.301 Further dilution with IV solutions is not recommended.301

Drug Compatibility
Syringe CompatibilityHID

Incompatible

Pantoprazole sodium

Y-Site CompatibilityHID

Compatible

Furosemide

Potassium chloride

Sodium bicarbonate

Sodium nitroprusside

Incompatible

Amino acid injection (TrophAmine)

Calcium gluconate

Cimetidine HCl

Dobutamine HCl

Dopamine HCl

Gentamicin sulfate

Levofloxacin

Tobramycin sulfate

Variable

Dextrose injection

Actions

  • Inhibits cyclooxygenase-1 (COX-1) and COX-2.301 341 420 455 456 457 458 461 462 463

  • Pharmacologic actions similar to those of other prototypical NSAIAs; exhibits anti-inflammatory, analgesic, and antipyretic activity.301 341 420

  • Permits closure of the ductus arteriosus in premature neonates by inhibiting prostaglandin synthesis.301

Advice to Patients

  • Importance of reading the medication guide for NSAIAs that is provided each time the drug is dispensed.420

  • Risk of serious cardiovascular events with long-term use.420

  • Risk of GI bleeding and ulceration.341 420

  • Risk of serious skin reactions.420 Risk of anaphylactoid and other sensitivity reactions.420

  • Risk of hepatotoxicity.341 420

  • Risk of ocular toxicity.341 420

  • Potential for drug to impair mental alertness; use caution when driving or operating machinery until effects on individual are known.341 420

  • Importance of notifying clinician if signs and symptoms of a cardiovascular event (chest pain, dyspnea, weakness, slurred speech) occur.420

  • Importance of notifying clinician if signs and symptoms of GI ulceration or bleeding, unexplained weight gain, or edema develops.341 420

  • Importance of discontinuing indomethacin and contacting clinician if rash or other signs of hypersensitivity (blisters, fever, pruritus) develop.420 Importance of seeking immediate medical attention if an anaphylactic reaction occurs.341 420

  • Importance of discontinuing therapy and contacting clinician immediately if signs and symptoms of hepatotoxicity (nausea, fatigue, lethargy, pruritus, jaundice, upper right quadrant tenderness, flu-like symptoms) occur.341 420

  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.341 420 Importance of avoiding indomethacin in late pregnancy (third trimester).341 420

  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.341 420

  • Importance of informing patients of other important precautionary information.341 420 (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Indomethacin

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Oral

Capsules

25 mg*

Indocin

Merck

Indomethacin Capsules

Clonmel, Mutual, Mylan, Par, Pliva, Sandoz, Teva

50 mg*

Indocin

Merck

Indomethacin Capsules

Clonmel, Mutual, Mylan, Par, Pliva, Sandoz, Teva

Capsules, extended-release

75 mg*

Indomethacin Extended-release Capsules

Inwood

Suspension

25 mg/5 mL

Indocin (with alcohol 1% and sorbic acid)

Merck

Rectal

Suppositories

50 mg*

Indomethacin Suppositories

G&W, PD-RX

Indomethacin Sodium

Routes

Dosage Forms

Strengths

Brand Names

Manufacturer

Parenteral

For injection, for IV use only

1 mg (of anhydrous indomethacin)

Indocin I.V.

Ovation

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 02/2014. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Indomethacin 25MG Capsules (TEVA PHARMACEUTICALS USA): 30/$15.99 or 60/$20.99

Indomethacin 50MG Capsules (TEVA PHARMACEUTICALS USA): 30/$15.99 or 60/$21.98

Indomethacin CR 75MG Controlled-release Capsules (SANDOZ): 30/$82.15 or 90/$208.97

AHFS DI Essentials. © Copyright, 2004-2014, Selected Revisions March 1, 2008. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

236. Mathe AA. False normal dexamethasone suppression test and indomethacin. Lancet. 1982; 2:714. [IDIS 157387] [PubMed 6126646]

300. Paulus HE. FDA Arthritis Advisory Committee meeting: postmarketing surveillance of nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1985; 28:1168-9. [IDIS 208792] [PubMed 4052129]

301. Ovation Pharmaceuticals. Indocin I.V. (indomethacin sodium trihydrate) prescribing information. Deerfield, IL; 2005 Sep.

302. Yeh TF, Luken JA, Thalji A et al. Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus—a double-blind controlled study. J Pediatr. 1981; 98:137-45. [IDIS 130423] [PubMed 7005415]

303. Harris JP, Merritt TA, Alexson CG et al. Parenteral indomethacin for closure of the patent ductus arteriosus: clinical experience with 67 preterm infants. Am J Dis Child. 1982; 136:1005-8. [IDIS 158440] [PubMed 7124692]

304. Smith IJ, Goss I, Congdon PJ. Intravenous indomethacin for patent ductus arteriosus. Arch Dis Child. 1984; 59:537-41. [IDIS 187709] [PubMed 6742874]

305. Merritt TA, Harris JP, Roghmann K et al. Early closure of the patent ductus arteriosus in very low-birth-weight infants: a controlled trial. J Pediatr. 1981; 99:281-6. [PubMed 7019406]

306. Gersony WM, Peckham GJ, Ellison RC et al. Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study. J Pediatr. 1983; 102:895-906. [IDIS 171119] [PubMed 6343572]

307. Ellison RC, Peckham GJ, Lang P et al. Evaluation of the preterm infant for patent ductus arteriosus. Pediatrics. 1983; 71:364-72. [PubMed 6338474]

308. Brash AR, Hickey DE, Graham TP et al. Pharmacokinetics of indomethacin in the neonate: relation of plasma indomethacin levels to response of the ductus arteriosus. N Engl J Med. 1981; 305:67-72. [IDIS 133356] [PubMed 7242577]

309. Mellander M, Leheup B, Lindstrom DP et al. Recurrence of symptomatic patent ductus arteriosus in extremely premature infants, treated with indomethacin. J Pediatr. 1984; 105:138-43. [IDIS 187665] [PubMed 6737129]

310. Yeh TF, Goldbarg HR, Henek T et al. Intravenous indomethacin therapy in premature infants with patent ductus arteriosus: causes of death and one-year follow-up. Am J Dis Child. 1982; 136:803-7. [IDIS 157904] [PubMed 7114004]

311. Jacob J, Gluck L, DiSessa T et al. The contribution of PDA in the neonate with severe RDS. J Pediatr. 1980; 96:79-87. [IDIS 111116] [PubMed 6892514]

312. Halliday HL. Indomethacin for persistent ductus arteriosus. Lancet. 1980; 2:314. [IDIS 125050] [PubMed 6105458]

313. Anon. I.V. indomethacin approved to close patent ductus arteriosus. FDA Drug Bull. 1985; 15:4-5. [PubMed 3996802]

314. Thalji AA, Car I, Yeh TF et al. Pharmacokinetics of intravenously administered indomethacin in premature infants. J Pediatr. 1980; 97:995-1000. [IDIS 129568] [PubMed 7441434]

315. Mahony L, Carnero V, Brett C et al. Prophylactic indomethacin therapy for patent ductus arteriosus in very-low-birth-weight infants. N Engl J Med. 1982; 306:506-10. [IDIS 145126] [PubMed 7035955]

316. Mahony L, Caldwell RL, Girod DA et al. Indomethacin therapy on the first day of life in infants with very low birth weight. J Pediatr. 1985; 106:801-5. [IDIS 199832] [PubMed 3998921]

317. Seyberth HW, Knapp G, Wolf D et al. Introduction of plasma indomethacin level monitoring and evaluation of an effective threshold level in very low birth weight infants with symptomatic patent ductus arteriosus. Eur J Pediatr. 1983; 141:71-6. [PubMed 6363085]

318. Smallhorn JF, Gow R, Olley PM et al. Combined noninvasive assessment of the patent ductus arteriosus in the preterm infant before and after indomethacin treatment. Am J Cardiol. 1984; 54:1300-4. [IDIS 193070] [PubMed 6507302]

319. Peckham GJ, Miettinen OS, Ellison RC et al. Clinical course to 1 year of age in premature infants with patent ductus arteriosus: results of a multicenter randomized trial of indomethacin. J Pediatr. 1984; 105:285-91. [IDIS 188414] [PubMed 6379136]

320. Maher P, Lane B, Ballard R et al. Does indomethacin cause extension of intracranial hemorrhages: a preliminary study. Pediatrics. 1985; 75:497-500. [IDIS 196838] [PubMed 3883305]

321. Page GG. Patent ductus arteriosus in the premature neonate. Heart Lung. 1985; 14:156-62. [PubMed 3882636]

322. Merritt TA, White CL, Coen RW et al. Preschool assessment of infants with a patent ductus arteriosus: comparison of ligation and indomethacin therapy. Am J Dis Child. 1982; 136:507-12. [PubMed 7091062]

323. Corazza MS, Davis RF, Merritt TA et al. Prolonged bleeding time in preterm infants receiving indomethacin for patent ductus arteriosus. J Pediatr. 1984; 105:292-6. [IDIS 188415] [PubMed 6747765]

324. Yeh TF, Wilks A, Singh J et al. Furosemide prevents the renal side effects of indomethacin therapy in premature infants with patent ductus arteriosus. J Pediatr. 1982; 101:433-7. [IDIS 157407] [PubMed 7108667]

325. Betkerur MV, Yeh TF, Miller K et al. Indomethacin and its effect on renal function and urinary kallikrein excretion in premature infants with patent ductus arteriosus. Pediatrics. 1981; 68:99-102. [IDIS 134101] [PubMed 6909683]

326. Seyberth HW, Rascher W, Hackenthal R et al. Effect of prolonged indomethacin therapy on renal function and selected vasoactive hormones in very-low-birth-weight infants with symptomatic patent ductus arteriosus. J Pediatr. 1983; 103:979-84. [IDIS 185844] [PubMed 6358443]

327. Law WM Jr, Heath H III. Familial benign hypercalcemia (hypocalciuric hypercalcemia): clinical and pathogenetic studies in 21 families. Ann Intern Med. 1985; 102:511-9. [PubMed 3977197]

328. Dzau VJ, Packer M, Lilly LS et al. Prostaglandins in severe congestive heart failure: relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med. 1984; 310:347-52. [PubMed 6361570]

329. Catterton Z, Sellers B, Gray B. Inulin clearance in the premature infant receiving indomethacin. J Pediatr. 1980; 96:737-9. [IDIS 113579] [PubMed 7359285]

330. Sanders DR, Kraff M. Steroidal and nonsteroidal anti-inflammatory agents: effect on postsurgical inflammation and blood-aqueous humor barrier breakdown. Arch Ophthalmol. 1984; 102:1453-6. [IDIS 191396] [PubMed 6385931]

331. Kraff MC, Sanders DR, Jampol LM et al. Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology. 1982; 89:885-90. [PubMed 6752799]

332. Kraff MC, Sanders DR, Peyman GA et al. Slit-lamp fluorophotometry in intraocular lens patients. Ophthalmology. 1980; 87:877-80. [PubMed 7413152]

333. Miyake K, Sakamura S, Miura H. Long-term follow-up study on prevention of aphakic cystoid macular oedema by topical indomethacin. Br J Ophthalmol. 1980; 64:324-8. [PubMed 7437393]

334. Yannuzzi LA, Landau AN, Turtz AI. Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmology. 1981; 88:947-54. [PubMed 7029388]

335. Miyake K. Indomethacin in the treatment of postoperative cystoid macular edema. Surv Ophthalmol. 1984; 28(Suppl):554-68. [PubMed 6379953]

336. Yamaaki H, Hendrikse F, Deutman F. Iris angiography after cataract extraction and the effect of indomethacin eyedrops. Ophthalmologica. 1984; 188:82-6. [PubMed 6709307]

337. Jampol LM. Pharmacologic therapy of aphakic and pseudophakic cystoid macular edema: 1985 update. Ophthalmology. 1985; 92:807-10. [PubMed 3897936]

338. Kraff MC, Sanders DR, Jampol LM et al. Factors affecting pseudophakic cystoid macular edema: five randomized trials. J Am Intraocul Implant Soc. 1985; 11:380-5. [PubMed 4030486]

339. Miyake K, Miyake Y, Maekubo K et al. Incidence of cystoid macular edema after retinal detachment surgery and the use of topical indomethacin. Am J Ophthalmol. 1983; 95:451-6. [IDIS 169359] [PubMed 6340512]

340. Sanders DR, Goldstick B, Kraff C et al. Aqueous penetration of oral and topical indomethacin in humans. Arch Ophthalmol. 1983; 101:1614-6. [IDIS 176803] [PubMed 6626018]

341. Eon Labs. Indomethacin extended-release capsules prescribing information. Laurelton, NY; 2000 Apr.

342. Ment LR, Duncan CC, Ehrenkranz RA et al. Randomized indomethacin trial for the prevention of intraventricular hemorrhage in very low birth weight infants. J Pediatr. 1985; 107:937-43. [IDIS 210014] [PubMed 3906073]

343. Setzer ES, Webb IB, Wassenaar JW et al. Platelet dysfunction and coagulopathy in intraventricular hemorrhage in the premature infant. J Pediatr. 100:599-605.

344. Lanza FL, Umbenhauer ER, Nelson RS et al. A double-blind randomized placebo controlled gastroscopic study to compare the effects of indomethacin capsules and indomethacin suppositories on the gastric mucosa of human volunteers. J Rheumatol. 1982; 9:415-9. [PubMed 6750118]

345. Hansen TM, Matzen P, Madsen P. Endoscopic evaluation of the effect of indomethacin capsules and suppositories on the gastric mucosa in rheumatic patients. J Rheumatol. 1984; 11:484-7. [PubMed 6332910]

346. Friedman Z, Whitman V, Maisels MJ et al. Indomethacin disposition and indomethacin-induced platelet dysfunction in premature infants. J Clin Pharmacol. 1978; 18:272-9. [PubMed 641216]

347. Harinck E, van Ertbruggen I, Senders RC et al. Problems with indomethacin for ductus closure. Lancet. 1977; 2:245. [IDIS 116267] [PubMed 69850]

348. Petersen S, Christensen NC et al. Serum indomethacin concentrations after intravenous administration to preterm infants with patent ductus arteriosus. Acta Paediatr Scand. 1981; 70:729-33. [PubMed 7324922]

349. Kennedy JD, Jones RCM, Hudson SA et al. Patent ductus arteriosus in premature babies. BMJ. 1982; 284:114-5.

350. Yanagi RM, Wilson A, Newfeld EA et al. Indomethacin treatment for symptomatic patent ductus arteriosus: a double-blind control study. Pediatrics. 1981; 67:647-52. [IDIS 131214] [PubMed 7019841]

351. Alpan G, Eyal F, Vinograd I et al. Localized intestinal perforations after enteral adminstration of indomethacin in premature infants. J Pediatr. 1985; 106:277-81. [IDIS 196194] [PubMed 3968618]

352. Campbell AN, Beasley JR, Kenna AP. Indomethacin and gastric perforation in a neonate. Lancet. 1981; 1:1110-1. [IDIS 131255] [PubMed 6112478]

353. Nagaraj HS, Sandhu AS, Cook LN et al. Gastrointestinal perforation following indomethacin therapy in very low birth weight infants. J Pediatr Surg. 1981; 16:1003-7. [PubMed 7338750]

354. Neal WA, Kyle JM, Mullett MD. Failure of indomethacin therapy to induce closure of patent ductus arteriosus in premature infants with respiratory distress syndrome. J Pediatr. 1977; 91:621-3. [IDIS 94300] [PubMed 908986]

355. Merritt TA, DiSessa TG, Feldman BH et al. Closure of patent ductus arteriosus with ligation and indomethacin: a consecutive experience. J Pediatr. 1978; 93:639-46. [IDIS 99814] [PubMed 279657]

356. Merritt TA, White CL, Jacob J et al. Patent ductus arteriosus treated with ligation or indomethacin: a follow-up study. J Pediatr. 1979; 95:588-94. [IDIS 102005] [PubMed 480040]

357. Friedman WF, Hirschklau MJ, Printz MP et al. Pharmacologic closure of patent ductus arteriosus in the premature infant. N Engl J Med. 1976; 295:526-9. [IDIS 62334] [PubMed 820994]

358. McCarthy JS, Zies LG, Gelband H. Age-dependent closure of the patent ductus arteriosus by indomethacin. Pediatrics. 1978; 62:706-12. [IDIS 118461] [PubMed 724314]

359. Heyman MA, Rudolph AM, Silverman NH. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med. 1976; 295:530-3. [IDIS 62335] [PubMed 950959]

360. Procianoy RS, Garcia-Prats JA, Hittner HM et al. Use of indomethacin and its relationship to retinopathy of prematurity in very low birthweight infants. Arch Dis Child. 1980; 55:362-4. [IDIS 118628] [PubMed 7436472]

361. Yeh TF, Raval D, Pyati S et al. Retinopathy of prematurity (ROP) and indomethacin therapy in premature infants with patent ductus arteriosus (PDA). Prostaglandins. 1983; 25:385-91. [PubMed 6346399]

362. Zimran A, Kramer M, Plaskin M et al. Incidence of hyperkalaemia induced by indomethacin in a hospital population. BMJ. 1985; 291:107-8. [IDIS 203189] [PubMed 3926071]

363. Rasmussen LF, Ahlfors CE, Wennberg RP. Displacement of bilirubin from albumin by indomethacin. J Clin Pharmacol. 1978; 18:477-81. [IDIS 102268] [PubMed 711930]

364. Yeh TF, Raval D, Lilien LD et al. Decreased plasma glucose after indomethacin therapy in premature infants with patent ductus arteriosus. Lancet. 1982; 2:104-5. [IDIS 153454] [PubMed 6123794]

365. Favre L, Glasson P, Vallotton MB. Reversible acute renal failure from combined triamterene and indomethacin. Ann Intern Med. 1982; 96:317-20. [IDIS 146179] [PubMed 6949485]

366. Weinberg MS, Quigg RJ, Salant DJ et al. Anuric renal failure precipitated by indomethacin and triamterene. Nephron. 1985; 40:216-8. [PubMed 4000350]

367. Williams RL, Davies RO, Berman RS et al. Hydrochlorothiazide pharmacokinetics and pharmacologic effect: the influence of indomethacin. J Clin Pharmacol. 1982; 22:32-41. [IDIS 148250] [PubMed 7061724]

368. Koopmans PP, Kateman WGPM, Tan Y et al. Effects of indomethacin and sulindac on hydrochlorothiazide kinetics. Clin Pharmacol Ther. 1985; 37:625-8. [IDIS 201890] [PubMed 3891188]

369. Koren G, Zarfin Y, Perlman M et al. Effects of indomethacin on digoxin pharmacokinetics in preterm infants. Pediatr Pharmacol. 1984; 4:25-30.

370. Zarfin Y, Koren G, Perlman M. Digoxin and indomethacin in preterm infants with PDA. J Pediatr. 1984; 105:678-9. [IDIS 190944] [PubMed 6481555]

371. John EG, Vasan U, Hastreiter AR et al. Intravenous indomethacin and changes of renal function in premature infants with patent ductus arteriosus. Pediatr Pharmacol. 1984; 4:11-9.

372. Zarfin Y, Koren G, Maresky D et al. Possible indomethacin-aminoglycoside interaction in preterm infants. J Pediatr. 1985; 106:511-3. [IDIS 197134] [PubMed 3973790]

373. Bennett WM, Aronoff GR, Golper TA et al. Drug prescribing in renal failure: dosing guidelines for adults. Philadelphia: American College of Physicians; 1987:74-5.

374. AMA Department of Drugs. AMA drug evaluations. 5th ed. Chicago: American Medical Association;

375. Settipane GA. Adverse reactions to aspirin and other drugs. Arch Intern Med. 1981; 141:328-32. [IDIS 142745] [PubMed 7008734]

376. Weinberger M. Analgesic sensitivity in children with asthma. Pediatrics. 1978; 62(Suppl):910-5. [IDIS 118712] [PubMed 103067]

377. Settipane GA. Aspirin and allergic diseases: a review. Am J Med. 1983; 74(Suppl):102-9. [IDIS 171763] [PubMed 6344621]

378. VanArsdel PP Jr. Aspirin idiosyncracy and tolerance. J Allergy Clin Immunol. 1984; 73:431-3. [IDIS 183975] [PubMed 6423718]

379. Stevenson DD. Diagnosis, prevention, and treatment of adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs. J Allergy Clin Immunol. 1984; 74(4 Part 2):617-22. [IDIS 193318] [PubMed 6436354]

380. Stevenson DD, Mathison DA. Aspirin sensitivity in asthmatics: when may this drug be safe? Postgrad Med. 1985; 78:111-3,116-9. (IDIS 205854)

381. The Upjohn Company. Motrin prescribing information. Kalamazoo, MI; 1985 Jul.

382. McNeil Pharmaceutical. Tolectin DS and Tolectin prescribing information. Spring House, PA; 1985 Aug.

383. Syntex Puerto Rico, Inc. Naprosyn prescribing information. Humacao, PR; 1985 Jun.

384. Pleskow WW, Stevenson DD, Mathison DA et al. Aspirin desensitization in aspirin-sensitive asthmatic patients: clinical manifestations and characterization of the refractory period. J Allergy Clin Immunol. 1982; 69(1 Part 1):11-9. [IDIS 144037] [PubMed 7054250]

385. Thyss A, Milano G, Kubar J et al. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet. 1986; 1:256-8. [IDIS 210465] [PubMed 2868265]

386. Ellison NM, Servi RJ. Acute renal failure and death following sequential intermediate-dose methotrexate and 5-FU: a possible adverse effect due to concomitant indomethacin administration. Cancer Treat Rep. 1985; 69:342-3. [IDIS 198404] [PubMed 3978662]

387. Singh RR, Malaviya AN, Pandey JN et al. Fatal interaction between methotrexate and naproxen. Lancet. 1986; 1:1390. [IDIS 217293] [PubMed 2872507]

388. Day RO, Graham GG, Champion GD et al. Anti-rheumatic drug interactions. Clin Rheum Dis. 1984; 10:251-75. [PubMed 6150784]

389. Daly HM, Scott GL, Boyle J et al. Methotrexate toxicity precipitated by azapropazone. Br J Dermatol. 1986; 114:733-5. [IDIS 217458] [PubMed 3718865]

390. Hansten PD, Horn JR. Methotrexate interactions: ketoprofen (Orudis). Drug Interact Newsl. 1986; 6(Updates):U5-6.

391. Hansten PD, Horn JR. Methotrexate and nonsteroidal anti-inflammatory drugs. Drug Interact Newsl. 1986; 6:41-3.

392. Maiche AG. Acute renal failure due to concomitant action of methotrexate and indomethacin. Lancet. 1986; 1:1390. [IDIS 217292] [PubMed 2872506]

393. Cinquegrani MP, Liang CS. Indomethacin attenuates the hypotensive action of hydralazine. Clin Pharmacol Ther. 1986; 39:564-70. [IDIS 216068] [PubMed 3698464]

394. Ment LR. Indomethacin for prevention of intraventricular hemorrhage. J Pediatr. 1986; 109:397-8.

395. Barrington KJ. Indomethacin for prevention of intraventricular hemorrhage. J Pediatr. 1986; 109:396-7. [PubMed 3525793]

396. Cowan F. Indomethacin, patent ductus arteriosus, and cerebral blood flow. J Pediatr. 1986; 109:341-4. [IDIS 219997] [PubMed 3734971]

397. Gordon RD, Tunny TJ, Klemm SA et al. Indomethacin and atrial natriuretic peptide in Bartter’s syndrome. N Engl J Med. 1986; 315:459. [IDIS 219396] [PubMed 2942775]

398. Vanhaesebrouck P, Thiery M, Leroy JG et al. Oligohydramnios, renal insufficiency, and ileal perforation in preterm infants after intrauterine exposure to indomethacin. J Pediatr. 1988; 113:738-43. [IDIS 247688] [PubMed 3050004]

399. Moise KJ, Huhta JC, Sharif DS et al. Indomethacin in the treatment of premature labor: effects on the fetal ductus arteriosus. N Engl J Med. 1988; 319:327-31. [IDIS 244665] [PubMed 3393194]

400. Krueger E, Mellander M, Bratton D et al. Prevention of symptomatic patent ductus arteriosus with a single dose of indomethacin. J Pediatr. 1987; 111:749-54. [IDIS 244839] [PubMed 3312552]

401. Clyman RI, Campbell D. Indomethacin therapy for patent ductus arteriosus: when is prophylaxis not prophylactic? J Pediatr. 1987; 111:718-22. Editorial.

402. Setzer Bandstra E, Montalvo BM, Goldberg RN et al. Prophylactic indomethacin for prevention of intraventricular hemorrhage in premature infants. Pediatrics. 1988; 82:533-42. [IDIS 246725] [PubMed 3174314]

403. Ment LR, Duncan CC, Ehrenkranz RA et al. Randomized low-dose indomethacin trial for prevention of intraventricular hemorrhage in very low birth weight neonates. J Pediatr. 1988; 112:948-55. [IDIS 243715] [PubMed 3373405]

404. Ramsay JM, Murphy DJ, Vick W III et al. Response of patent ductus arteriosus to indomethacin treatment. Am J Dis Child. 1987; 141:294-7. [IDIS 226307] [PubMed 3812411]

405. Hanigan WC, Kennedy G, Roemisch F et al. Administration of indomethacin for the prevention of periventricular-intraventricular hemorrhage in high-risk neonates. J Pediatr. 1988; 112:941-7. [IDIS 243714] [PubMed 3373404]

406. Palmer JF. Letter sent to Berger ET, of Merck Sharp & Dohme regarding labeling revisions about gastrointestinal adverse reactions to Indocin (indomethacin). Rockville, MD: Food and Drug Administration, Division of Oncology and Radiopharmaceutical Drug Products; 1988 Sep.

407. Food and Drug Administration. Labeling revisions for NSAIDs. FDA Drug Bull. 1989; 19:3-4.

408. Searle. Cytotec (misoprostol) prescribing information. Skokie, IL; 1989 Jan.

409. Anon. Drugs for rheumatoid arthritis. Med Lett Drugs Ther. 2000; 42:57-64. [PubMed 10887424]

410. Soll AH, Weinstein WM, Kurata J et al. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med. 1991; 114:307-19. [IDIS 277370] [PubMed 1987878]

411. Digoxin/indomethacin. In: Tatro DS, Olin BR, eds. Drug interaction facts. St. Louis: JB Lippincott Co; 1991:285.

412. Jorgensen HS, Christensen HR, Kampmann JP. Interaction between digoxin and indomethacin or ibuprofen. Br J Clin Pharmacol. 1991; 31:108-10. [IDIS 277049] [PubMed 2015162]

413. Sandler DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med. 1991; 115:165-72. [IDIS 283815] [PubMed 2058870]

414. Wagner EH. Nonsteroidal anti-inflammatory drugs and renal disease—still unsettled. Ann Intern Med. 1991; 115:227-8. [IDIS 283820] [PubMed 2058878]

415. Stillman MT, Schlesinger PA. Nonsteroidal anti-inflammatory drug nephrotoxicity: should we be concerned? Arch Intern Med. 1990; 150:268-70.

416. Murray MD, Brater DC. Adverse effects of nonsteroidal anti-inflammatory drugs on renal function. Ann Intern Med. 1990; 112:559-60. [IDIS 265587] [PubMed 2327675]

417. Finch MB, Johnston GD, McDevitt DG. Pharmacokinetics of digoxin alone and in the presence of indomethacin therapy. Br J Clin Pharmacol. 1984; 17:353-5. [IDIS 184093] [PubMed 6712868]

418. Murray MD, Brater DC, Tierney WM et al. Ibuprofen-associated renal impairment in a large general medicine practice. Am J Med Sci. 1990; 299:222-9. [IDIS 301521] [PubMed 2321664]

419. Reviewers’ comments (personal observations).

420. Merck. Indocin (indomethacin) capsules, oral suspension, and suppositories prescribing information. Whitehouse Station, NJ; 2007 Mar.

421. Merck, West Point, PA: Personal communication.

422. Coombs RC, Morgan MEI, Durbin GM et al. Gut blood flow velocities in the newborn: effects of patent ductus arteriosus and parenteral indomethacin. Arch Dis Child. 1990; 65:1067-71. [IDIS 273669] [PubMed 2241229]

423. Rajadurai VS, Yu VYH. Intravenous indomethacin therapy in preterm neonates with patent ductus arteriosus. J Paediatr Child Health. 1991; 27:370-5. [PubMed 1756081]

424. Edwards AD, Wyatt JS, Richardson C et al. Effects of indomethacin on cerebral haemodynamics in very preterm infants. Lancet. 1990; 335:1491-5. [IDIS 267540] [PubMed 1972434]

425. Colditz P, Murphy D, Rolfe P et al. Effect of infusion rate of indomethacin on cerebrovascular responses in preterm infants. Arch Dis Child. 1989; 64:8-12. [IDIS 249853] [PubMed 2923488]

426. Pryds O, Greisen G, Johansen KH. Indomethacin and cerebral blood flow in premature infants treated for patent ductus arteriosus. Eur J Pediatr. 1988; 147:315-6. [PubMed 3391227]

427. Evans DH, Levene MI, Archer LNJ. The effect of indomethacin on cerebral blood-flow velocity in premature infants. Dev Med Child Neurol. 1987; 29:776-82. [PubMed 3691977]

428. Mardoum R, Bejar R, Merritt TA et al. Controlled study of the effects of indomethacin on cerebral blood flow velocities in newborn infants. J Pediatr. 1991; 118:112-5. [IDIS 276665] [PubMed 1986076]

429. Hammerman C, Glaser J, Schimmel MS et al. Continuous versus multiple rapid infusions of indomethacin: effects on cerebral blood flow velocity. Pediatrics. 1995; 95:244-8. [IDIS 342453] [PubMed 7838642]

430. Austin NC, Pairaudeau PW, Hames TK et al. Regional cerebral blood flow velocity changes after indomethacin infusion in preterm infants. Arch Dis Child. 1992; 67:851-4. [IDIS 300009] [PubMed 1519988]

431. Simko A, Mardoum R, Merritt TA et al. Effects on cerebral blood flow velocities of slow and rapid infusion of indomethacin. J Perinatol. 1994; 14:29-35. [PubMed 8169675]

432. Hollander D. Gastrointestinal complications of nonsteroidal anti-inflammatory drugs: prophylactic and therapeutic strategies. Am J Med. 1994; 96:274-81. [IDIS 328041] [PubMed 8154516]

433. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bledding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 1994; 343:769-72. [IDIS 328176] [PubMed 7907735]

434. Schubert TT, Bologna SD, Yawer N et al. Under risk factors: interaction between Helicobacter pylori infection, nonsteroidal use, and age. Am J Med. 1993; 94:413-7. [IDIS 314155] [PubMed 8475935]

435. Bateman DN, kennedy JG. Non-steroidal anti-inflammatory drugs and elderly patients: the medicine may be worse that than the disease. BMJ. 1995; 310:817-8. [IDIS 345154] [PubMed 7711609]

436. Corticosteroid interactions: nonsteroidal anti-inflammatory drugs (NSAIDs). In: Hansten PD, Horn JR. Drug interactions and updates. Vancouver, WA: Applied Therapeutics, Inc; 1993:562.

437. Piper JM, Ray WA, Daugherty JR et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Am Intern Med. 1991; 114:735-40.

438. Geigy, Ardsley, NY: Personal communication on diclofenac 28:08.04.

439. Reviewers’ comments (personal observation) on diclofenac 28:08.04.

440. McNeil. Motrin (ibuprofen suspension, chewale tablets, caplets) prescribing information. Fort Washington, PA; 1994 Dec.

441. Abe K, Ito T, Sato M et al. Role of prostaglandin in the antihypertensive mechanism of captopril in low renin hypertension. Clin Sci. 1980; 59:141-4s.

442. Antiotensin-converting enzyme inhibitor interactions: nonsteroidal anti-inflammatory drugs (NSAIDs). In: Hansten PD, Horn JR. Drug interactions and updates. Vancouver, WA: Applied Therapeutics, Inc; 1993:131-2.

443. ACE inhibitors/indomethacin. In: Tatro DS, olin BR, Hebel SK et al. Drug interaction facts. St. Louis: JB Lippincott Co; 1992(April):28.

444. Salvetti A, Abdel-Haq B, Magagna A et al. Indomethacin reduces the antihypertensive action of enalapril. Clin Exp Hypertens. 1987; 9:559-67.

445. Fujita T. Yamashita N, Yamashita K. Effect of indomethacin on antihypertensive action of captopril in hypertensive patients. Clin Exp Hypertens. 1981; 3:939-52. [PubMed 7026199]

446. Moore TJ, Crantz FR, Hollenberg NK et al. Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension. Hypertension. 1981; 3:168-73. [PubMed 6260645]

447. Silberbauer K, Stanek B, Templ H. Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition. Br J Clin Pharmacol. 1982; 14(Suppl 2):87-93S.

448. Seelig CB, Maloley PA, Campbell JR. Nephrotoxicity associated with concomitant ACE inhibitor and NSAID therapy. South Med J. 1990; 83:1144-8. [PubMed 2218652]

449. Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. Neurology. 1996; 46:1470. [PubMed 8628505]

450. Schatz IJ. Farewell to the “Shy-Drager syndrome”. Ann Intern Med. 1996; 125:74-5. [PubMed 8644992]

451. Sidmak Laboratories. Indomethacin capsules, USP, prescribing information. East Hanover, NJ; 1996 June.

452. Ryan TJ, Antman EM, Brooks NH et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: 1999 update: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). From website.

453. Friedman PL, Brown EJ Jr, Gunther S et al. Coronary vasoconstrictor effect of indomethacin in patients with coronary-artery disease. N Engl J Med. 1981; 305:1171-5. [IDIS 140447] [PubMed 7290132]

454. Hammerman H, Schoen FJ, Braunwald E et al. Drug-induced expansion of infarct: morphologic and functional correlations. Circulation. 1984; 69:611-7. [PubMed 6692521]

455. Cryer B, Dubois A. The advent of highly selective inhibitors of cyclooxygenase—a review. Prostaglandins Other Lipid Mediators. 1998; 56:341-61. [PubMed 9990677]

456. Simon LS. Role and regulation of cyclooxygenase-2 during inflammation. Am J Med. 1999; 106(Suppl 5B):37-42S.

457. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999; 340:1888-99. [IDIS 426864] [PubMed 10369853]

458. Hawkey CJ. COX-2 inhibitors. Lancet. 1999; 353:307-14. [IDIS 418284] [PubMed 9929039]

459. Morrison BW, Daniels SE, Kotey P et al. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled study. Obstet Gynecol. 1999;94:504-8.

461. Kurumbail RG, Stevens AM, Gierse JK et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 1996; 384:644-8. [PubMed 8967954]

462. Riendeau D, Charleson S, Cromlish W et al. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Can J Physiol Pharmacol. 1997; 75:1088-95. [PubMed 9365818]

463. DeWitt DL, Bhattacharyya D, Lecomte M et al. The differential susceptibility of prostaglandin endoperoxide H synthases-1 and -2 to nonsteroidal anti-inflammatory drugs: aspirin derivatives as selective inhibitors. Med Chem Res. 1995; 5:325-43.

464. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002; 46:328-46. [IDIS 476480] [PubMed 11840435]

465. Vermillion ST, Newman RB. Recent indomethacin tocolysis is not associated with neonatal complications in preterm infants. Am J Obstet Gynecol. 1999; 181:1083-6. [IDIS 438886] [PubMed 10561622]

466. Abramov Y, Nadjari M, Weinstein D et al. Indomethacin for preterm labor: a randomized comparison of vaginal and rectal-oral routes. Obstet Gynecol. 2000; 95:482-6. [IDIS 445446] [PubMed 10725476]

467. Katz VL, Farmer RM. Controversies in tocolytic therapy. Clin Obstet Gynecol. 1999; 42:802-19. [PubMed 10572695]

468. Higby K, Suiter CR. A risk-benefit assessment of therapies for premature labour. Drug Saf. 1999; 21:35-56. [PubMed 10433352]

469. Macones GA, Robinson CA. Is there justification for using indomethacin in preterm labor? An analysis of neonatal risks and benefits. Am J Obstet Gynecol. 1997; 177:819-24. [IDIS 397293] [PubMed 9369826]

470. Panter KR, Hannah ME, Amankwah KS et al. The effect of indomethacin tocolysis in preterm labour on perinatal outcome: a randomised placebo-controlled trial. Br J Obstet Gynecol. 1999; 106:467-73.

471. Lanza FL, and the members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol. 1998; 93:2037-46. [IDIS 417402] [PubMed 9820370]

472. Schmidt B, Davis P, Moddemann D et al. Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants. N Engl J Med. 2001; 344:1966-72. [IDIS 465942] [PubMed 11430325]

473. Hammerman C, Kaplan M. Comparative tolerability of pharmacological treatments for patent ductus arteriosus. Drug Safety. 2001; 24:537-51. [PubMed 11444725]

474. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol. 1999; 26(suppl 56):18-24.

475. in’t Veld BA, Ruitenberg A, Hofman A et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med. 2001; 345:1515-21. [PubMed 11794217]

476. Breitner JCS, Zandi PP. Do nonsteroidal antiinflammatory drugs reduce the risk of Alzheimer’s disease? N Engl J Med. 2001; 345:1567-8. Editorial.

477. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies. Neurology. 1996; 47:425-32. [IDIS 371394] [PubMed 8757015]

478. Beard CM, Waring SC, O’sBrien PC et al. Nonsteroidal anti-inflammatory drug use and Alzheimer’s disease: a case-control study in Rochester, Minnesota, 1980 through 1984. Mayo Clin Proc. 1998; 73:951-5. [IDIS 416502] [PubMed 9787743]

479. in’t Veld BA, Launer LJ, Hoes AW et al. NSAIDs and incident Alzheimer’s disease: the Rotterdam Study. Neurobiol Aging. 1998; 19:607-11. [PubMed 10192221]

480. Stewart WF, Kawas C, Corrada M et al. Risk of Alzheimer’s disease and duration of NSAID use. Neurology. 1997; 48:626-32. [IDIS 383303] [PubMed 9065537]

481. Pharmacia. Daypro (oxaprozin) caplets prescribing information. Chicago, IL; 2002 May.

482. Chan FKL, Hung LCT, Suen BY et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002; 347:2104-10. [IDIS 490812] [PubMed 12501222]

483. Graham DY. NSAIDs, Helicobacter pylori, and Pandora’s box. N Engl J Med. 2002; 347:2162-4. [IDIS 490815] [PubMed 12501230]

484. Food and Drug Administration. Analysis and recommendations for agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk. 2005 Apr 6.

485. Cush JJ. The safety of COX-2 inhibitors: deliberations from the February 16-18, 2005, FDA meeting. From the American College of Rheumatology website (). Accessed 2005 Oct 12.

486. Novartis Pharmaceuticals. Diovan (valsartan) capsules prescribing information (dated 1997 Apr). In: Physicians’ desk reference. 53rd ed. Montvale, NJ: Medical Economics Company Inc; 1999:2013-5.

487. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006; 296; 1633-44. [PubMed 16968831]

488. Kearney PM, Baigent C, Godwin J et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006; 332; 1302-5. [PubMed 16740558]

489. Graham DJ. COX-2 inhibitors, other NSAIDs, and cardiovascular risk; the seduction of common sense. JAMA. 2006; 296:1653-6. [PubMed 16968830]

490. Chou R, Helfand M, Peterson K et al. Comparative effectiveness and safety of analgesics for osteoarthritis. Comparative effectiveness review no. 4. (Prepared by the Oregon evidence-based practice center under contract no. 290-02-0024.) . Rockville, MD: Agency for Healthcare Research and Quality. 2006 Sep. Available at: .

a. AHFS drug information 2003. McEvoy GK, ed. Indomethacin/Indomethacin Sodium. Bethesda, MD: American Society of Health-System Pharmacists; 2003;1954-64.

b. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:705-14.

HID. Trissel LA. Handbook on injectable drugs. 14th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2007:940-1.

Hide
(web4)